EGFR Mutant NSCLC: Expert Perspectives in Testing and Targeted Therapy

Moderator Zofia Piotrowska, MD, MHS introduces an upcoming Onclive Peer Exchange discussion with expert panelists concerning recent updates from in the diagnosis and treatment of EGFR Mutant NSCLC.

EP. 1: Treatment Options for Stage I-IIIA NSCLC

July 17th 2023

After a brief introduction, Lyudmila Bazhenova, MD reviews treatment options for early-stage NSCLC, the prevalence of EGFR mutations, and guidelines for managing patients with stage 1b resectable disease.

EP. 2: ADAURA Trial: Adjuvant Osimertinib and Clinical Implications

July 17th 2023

The panelists explore the groundbreaking ADAURA trial, covering its study design, efficacy and safety results, and the current clinical implications.

EP. 3: Latest Overall Survival Analyses in Resected EGFR-Mutated NSCLC

July 24th 2023

Analyzing a recent overall survival analysis from the ADAURA trial, its impact on practice, and changes in the treatment landscape of early NSCLC.

EP. 4: Routine Molecular Testing in Early NSCLC Post-Resection

July 24th 2023

Recommendations for community oncologists concerning molecular testing, including the types of tests, timing best practices, and how the results should inform treatment decisions.

EP. 5: Selecting Appropriate Adjuvant Therapy for Patients with EGFR-Mutant NSCLC

July 31st 2023

On the subject of patient eligibility, the panel deliberates on the decision-making process between osimertinib and chemotherapy and outlines adjuvant therapy options.

EP. 6: Role of Neoadjuvant Therapy in Resectable NSCLC

July 31st 2023

Insights on the use of neoadjuvant therapy in resectable NSCLC, particularly focusing on the use of neoadjuvant IO in EGFR mutated patients and the results of relevant trials.